携带表面活性物质相关基因突变的成人肺纤维化患者疾病进展且生存率低:一项观察性研究
该回顾性观察研究从20个家系48例SRG突变患者中筛选出23例有随访数据的成人ILD患者,与248例家族性肺纤维化(FPF)和575例散发性特发性肺纤维化(sIPF)患者比较。SRG组诊断时更年轻、男性更少,但FVC(72%预计值)和DLCO(46%预计值)更低。SRG组诊断后6个月FVC中位下降-40 mL,中位无移植生存44个月,与FPF或sIPF无差异;三组FVC变化无差异,但接受免疫调节或抗纤维化治疗者FVC下降幅度显著大于未治疗者。SRG组后续分析显示,7例接受抗纤维化药物6个月的患者肺功能稳定,FVC中位变化+40 mL(四分位距-40至90 mL),而免疫调节治疗的反应因涉及基因而异。
要点
- SRG突变成人ILD诊断时中位年龄45岁,FVC 72%预计值、DLCO 46%预计值,低于FPF或sIPF患者。
- SRG组诊断后6个月FVC中位下降-40 mL,中位无移植生存44个月,与FPF或sIPF无差异。
- 三组FVC变化无差异,但接受免疫调节或抗纤维化治疗者FVC下降显著大于未治疗者。
- SRG组7例接受抗纤维化药物6个月者肺功能稳定,FVC中位变化+40 mL(四分位距-40至90 mL)。
- SRG组免疫调节治疗反应因涉及基因而异。
适用人群与场景
- 成人ILD患者,携带表面活性物质相关基因(SRG)突变,包括SFTPC、SFTPA2或ABCA3。
- 从20个家系48例SRG突变患者中筛选,23例有临床随访数据并符合标准。
- 对照人群为248例家族性肺纤维化(FPF)和575例散发性特发性肺纤维化(sIPF)患者。
处置流程与药物剂量
- SRG组中7例接受抗纤维化药物治疗6个月,肺功能稳定,FVC中位变化+40 mL(四分位距-40至90 mL)。
- SRG组接受免疫调节药物治疗者反应不一,取决于所涉及的基因。
研究设计与关键结果
- 研究类型:回顾性观察性研究;SRG组23例(中位年龄45岁;11例男性),对照为248例FPF和575例sIPF患者。
- SRG组诊断时较FPF或sIPF患者更年轻、男性更少,但FVC(72%预计值)和DLCO(46%预计值)更低。
- SRG组诊断后6个月FVC中位下降-40 mL,中位无移植生存44个月,与FPF或sIPF患者无差异。
- 三组间FVC变化无差异;但接受免疫调节或抗纤维化治疗者FVC下降幅度显著大于未治疗者。
- SRG组7例接受抗纤维化药物6个月者肺功能稳定,FVC中位变化+40 mL(四分位距-40至90 mL);免疫调节治疗反应因基因而异。
证据类型、等级与局限
- 证据类型:观察性研究(回顾性队列)。
- 局限:原文未报告局限性。
对床旁实践的改变
- SRG突变成人ILD患者诊断时肺功能已较低,中位无移植生存44个月,提示预后不良。
- 抗纤维化药物治疗6个月在7例SRG突变患者中显示肺功能稳定(FVC中位变化+40 mL),但样本量小。
- 免疫调节治疗的反应因基因而异,且治疗期间FVC下降更大,需个体化评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In some patients with progressive fibrosing interstitial lung disease (ILD), disease is caused by carriage of a mutation in a surfactant-related gene (SRG) such as SFTPC, SFTPA2, or ABCA3. However, no aggregated data on disease evolution and treatment outcome have been presented for these patients.
RESEARCH QUESTION: In adult patients with ILD with an SRG mutation, what is the course of lung function after diagnosis and during treatment and the survival in comparison with patients with sporadic idiopathic pulmonary fibrosis (sIPF) and familial pulmonary fibrosis (FPF)?
STUDY DESIGN AND METHODS: We retrospectively examined the clinical course of a cohort of adults with an SRG mutation by screening 48 patients from 20 families with an SRG mutation for availability of clinical follow-up data. For comparison, 248 patients with FPF and 575 patients with sIPF were included.
RESULTS: Twenty-three patients with ILD (median age: 45 years; 11 men) with an SRG mutation fulfilled criteria. At diagnosis, patients with an SRG mutation were younger and less often male, but had lower FVC (72% predicted) and diffusing capacity of the lungs for carbon monoxide (46% predicted) compared with patients with FPF or sIPF. In the SRG mutation group, median FVC decline 6 months after diagnosis was -40 mL and median transplant-free survival was 44 months and not different from patients with FPF or sIPF. FVC course was not different among the three cohorts; however, a significantly larger decrease in FVC was found while patients received immunomodulatory or antifibrotic treatment compared with those receiving no treatment. Subsequent analysis in the SRG group showed that patients with a surfactant mutation (n = 7) treated for 6 months with antifibrotic drugs showed stable lung function with a median change in FVC of +40 mL (interquartile range, -40 to 90 mL), whereas patients with an SRG mutation treated with immunomodulatory drugs showed a variable response dependent on the gene involved.
INTERPRETATION: This study showed that patients with ILD carrying an SRG mutation experience progressive loss of lung function with severely reduced survival despite possible beneficial effects of treatment.
参考来源
- Klay D, Grutters JC, van der Vis JJ, et al. Progressive Disease With Low Survival in Adult Patients With Pulmonary Fibrosis Carrying Surfactant-Related Gene Mutations: An Observational Study. Chest. 2022. PMID: 36370864. doi:10.1016/j.chest.2022.11.002
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。